The U.S. Food and Drug Administration (FDA) yesterday (March 31) unveiled the Coronavirus Treatment Acceleration Program (CTAP), which is designed to use “every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.”

The U.S. Food and Drug Administration (FDA) today (March 30) issued a temporary guidance intended to expand the availability of surgical apparel for healthcare professionals, including gowns (togas), hoods, and surgeon’s and patient examination gloves, during the COVID-19 pandemic. The guidance is being implemented without solicitation of prior public comments because the FDA has […]

Dartmouth-Hitchcock Health just helped open two Phase III COVID-19–related therapeutic studies in six business days. The Gilead-sponsored studies, one of patients with moderate COVID-19 and the other with patients suffering more serious symptoms, are evaluating the safety and antiviral activity of Remdesivir (GS-5734™) against the condition.